Antibiotic resistance has become one of our most pressing health challenges. To address this global health issue, Kinvard Bio, a startup out of the Myers Lab at Harvard University, is developing a new class of antibiotics that target drug-resistant infections and diseases. Their innovative approach holds promise for overcoming pre-existing resistance, offering hope for effective treatments against a broad range of pathogens. While at the Myers Lab, the research team received funding and support from the Blavatnik Biomedical Accelerator and CARB-X. Kineticos Life Sciences provided support through its AMR Accelerator Fund I to launch the company. Co-founders Ben Tresco and Kelvin Wu, former graduate students in the Myers Lab who led the research, joined CEO Lloyd Payne at Kinvard to advance the innovations. Kinvard Bio is focused on acute and chronic drug-resistant infections, including bacterial pneumonia, complicated urinary tract infections, and chronic respiratory infections, with both intravenous and oral formulations. These advancements aim to enhance treatment efficacy and reduce hospital stays, minimizing the risk of acquiring secondary infections. https://lnkd.in/ezUdvMp7 #translationalresearch #universitystartup #Harvardstartup #BlavatnikBiomedicalAccelerator
Harvard Office of Technology Development (OTD)
Research Services
Cambridge, MA 17,640 followers
About us
Harvard’s research enterprise is a wellspring of innovation with the potential to improve lives, transform industries, and create tremendous social and economic value. We make that a reality.
- Website
-
http://otd.harvard.edu
External link for Harvard Office of Technology Development (OTD)
- Industry
- Research Services
- Company size
- 11-50 employees
- Headquarters
- Cambridge, MA
Updates
-
Thank you, Yelena Bisharyan, PhD and Karen Sinclair, for sharing your insights with Harvard Business School's MS/MBA students. As leaders within the #OTD team, Yelena and Karen spoke with students about commercializing innovations and bridging the gap between scientific research and real-world application.
Director Of Business Development at Harvard University, Office of Technology Development
The 21st century is an era of groundbreaking life science discoveries, and turning these innovations into patient solutions requires leaders who bridge science and business. Harvard Business School’s MS/MBA Program equips students with cutting-edge scientific and management insights to drive transformative biotech advancements. My colleague Karen Sinclair and I enjoyed presenting Harvard Office of Technology Development (OTD)’s approach to technology development, lab-to-market strategy, intellectual property, and more. It was inspiring to engage with a room full of future leaders and contribute to their learning journey.
-
-
A team of surgeons at the Massachusetts General Hospital has successfully completed the second transplant of a genetically edited pig kidney into a living patient. The donor kidney was developed by eGenesis, Inc., a xenotransplantation therapy company co-founded by Harvard Medical School Professor George Church and former HMS postdoctoral fellow Luhan Yang, with support from the Wyss Institute at Harvard University. The patient has been discharged from the hospital and is no longer on dialysis for the first time in over two years.
A team at Massachusetts General Hospital led by Harvard Medical School physician-scientists has for the second time successfully transplanted a genetically edited pig kidney into a living person. The team performed the first surgery of its kind in the world in March 2024. Results of the latest procedure highlight the promise of xenotransplantation — the transplanting of modified animal organs into humans — to alleviate human organ shortages and save lives. The approach could also help reduce health disparities in organ failure and access to transplantation. “This second xenotransplant provides us with another excellent opportunity to learn how we can make genetically edited pig organs a viable, long-term solution for patients,” says lead surgeon Tatsuo Kawai, HMS professor of surgery and director of the Legorreta Center for Clinical Transplant Tolerance at Mass General. “Although we have a long way to go to make that a reality, this transplant is an important next step that has given us optimism to achieve that goal.” The patient, 66-year-old New Hampshire resident Tim Andrews, is the fourth person in the world to receive a pig kidney. Two more kidney xenotransplants are scheduled to take place at Mass General in 2025. Read more about the surgery: https://bit.ly/414IyA2
-
-
-
-
-
+1
-
-
Scientists from Harvard Medical School examine why the microbiome is linked to many health issues.
There’s no question the microbiome profoundly shapes our health. But how? To find out, chemists are identifying the specific molecules these microbes produce and the effects they have on our health. Their discoveries are helping to move microbiome research from correlation to causation. “If we in the lab could discover a small molecule that’s beneficial, then a pharmaceutical company could take up that idea and use it as a starting point, and make a drug out of it,” says Sloan Devlin, an HMS associate professor of biological chemistry and molecular pharmacology. “Alternatively, if a detrimental molecule were discovered, the goal would be to prevent bacteria from making it in the first place.” Read about how researchers are decoding the chemistry of the microbiome: https://bit.ly/3Ct9Q9R
-
Thank you to the Harvard Grid and other Harvard organizers for creating a platform where founders can connect and form powerful interdisciplinary teams.
Last week, we hosted the Venturing@Harvard series in collaboration with the Harvard Innovation Labs, HBS Rock Center for Entrepreneurship, Lemann Center for Creativity and Entrepreneurship, and the Harvard HealthLab Accelerator bringing together company founders and potential collaborators. Founders pitched groundbreaking ideas, from merging neuroscience and AI in the biotech industry to public service ventures aimed at improving financial literacy among Peruvian women. The event showcased the innovative and impactful work happening at Harvard, providing a unique platform for founders to connect with partners and build interdisciplinary teams. For more events celebrating Harvard's entrepreneurial spirit, please visit the Harvard Grid website. There's much more to come! #HarvardGrid #Venturing@Harvard #Innovation #venturing
-
Congratulations to Harvard School of Dental Medicine for a successful Innovation Symposium. The full-day event gathered innovators, thought leaders, and entrepreneurs to discuss the future impact in oral healthcare. #OTD's Yelena Bisharyan, PhD and Peter Sollins presented on translating academic innovations into real-world solutions and the critical role of IP protection, followed by a panel discussion. Thanks to David T. Wu and the symposium organizers for orchestrating such a successful event.
Last week, over 80 participants gathered at HSDM for the inaugural Innovation Symposium, an exciting event that featured a dynamic mix of industry experts, entrepreneurs, and leaders in clinical innovation and translational medicine. The symposium featured several engaging panel sessions ranging from innovating processes for oral healthcare advancement to developing intellectual property and technology and translating scientific discoveries into clinical applications. "It was truly a special avenue uniting a community of leaders and pioneers at the intersection of academia, industry, and clinical innovation to connect with the HSDM community, and feature our student and faculty innovators to envision how we can bridge creative ideas to developing technologies and therapeutics that can transform the future of oral healthcare," said David Wu, instructor in Oral Medicine, Infection, and Immunity and organizer of the event. PC: Martin Haugstad, DMD25
-
-
Join us for the Biomedical Informatics Entrepreneur Salon (BIES) TODAY, featuring Garrett Frampton from Foundation Medicine, a leader in cancer genomic profiling. 🗓 Date: January 28th, 2025 🕒 Time: 4:30 PM to 6:00 PM (In-person) | 5:00 PM to 6:00 PM (Online via Zoom) 📍 Location: Harvard Medical School, Gordon Hall Room 106, The Waterhouse Room Garrett Frampton, Vice President and leader of the Foundation Medicine Computational Discovery group, has over 14 years of expertise in computational cancer research. This event will provide an opportunity to gain insights from Garrett's extensive experience in computational biology, cancer genomics, and clinical research. Register here: https://lnkd.in/eUqmsdcs #BEIS is co-hosted by #OTD and Harvard Medical School Department of Biomedical Informatics. Today's salon will be hosted by Moran Cabili-Kalmar, computational biologist and Associate Director of Business Development at OTD. We look forward to seeing you there! #BiomedicalInformatics #CancerResearch #Entrepreneurship #HarvardMedicalSchool #HealthcareInnovation
-
LAB eN², a translational drug discovery accelerator founded by Evotec and Novo Nordisk, announced the initial three academic projects to be supported by the accelerator. One of the projects, led by Dr. Sloan Devlin at Harvard Medical School, in collaboration with Dr. Eric Sheu at Mass General Brigham, aims to develop novel therapeutic candidates for the potential treatment of metabolic syndrome, including insulin resistance and type 2 diabetes. https://lnkd.in/eFPbZMTc
-
Nature inspires—even parasites. A new interdisciplinary effort led by Professor Robert Wood at Harvard John A. Paulson School of Engineering and Applied Sciences (#SEAS) and James Weaver at Wyss Institute at Harvard University examined tapeworms and other parasites for inspiration on tissue-attaching medical device design. #OTD is exploring commercialization opportunities for this #translationalresearch.
Using inspiration from the natural world of tapeworms and other parasites, SEAS researchers have crafted an innovative tissue-anchoring mechanism, described in PNAS Nexus. The technology has potential uses in diagnostics and minimally invasive surgeries, providing a less damaging and more efficient way to study and treat hard-to-access tissues. Beyond medical uses, the device's versatility hints at other applications like wildlife monitoring and textile-based sensing. “We’re really excited about applying the lessons learned from these studies to further broaden the design space to include other parasitic body plans, and other biological tissues and therapeutic applications,” said SEAS doctoral candidate and research team member Rachel Zoll.
-
-
Congratulations to Wyss Institute at Harvard University on its 15th year of breakthrough discoveries and advancing academic innovations from the lab toward real-world solutions!
The Wyss' fifteenth year was full of incredible achievements and milestones, including: ✍ Over 151 papers in peer-reviewed journals with Wyss authors 💡 Six Wyss-developed technologies licensed through Harvard OTD 🐷 First successful organ transplant from a pig donor, where the modified kidney was prepped by Wyss startup eGenesis, Inc. Take a look back on these and other highlights from 2024. #YearInReview https://lnkd.in/e-6bZKXB
-